Bay City Capital
Bay City Capital LLC (Bay City Capital), established in 1997 , specializes in investments in the life sciences industry.
Business Model:
Revenue: $8.4M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Bay City Capital Information
Geographic Data
Address: 750 Battery St
City: San Francisco
State: CA
Zip: 94111
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2M
Social
Twitter
Linkedin
Crunchbase
Metrics
7,558,103Website Global Rank
502Website Monthly Traffic
Twitter Followers
Description
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition and agribusiness sector fund.
Contact Phone:
+14156763830
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2013 | Interleukin Genetics | Post-IPO Equity | 12M |
| 12/1997 | Chemdex | Seed Round | - |
| 3/2000 | AquaBounty Technologies | Venture Round | - |
| 11/2002 | Pathway Diagnostics | Venture Round | - |
| 4/2000 | Ingenuity Systems | Venture Round | - |
| 7/2005 | BrainCells | Series A | 0 |
| 3/2008 | IDEV Technologies | Series C | 14.4M |
| 2/2006 | NeoRX Corporation (Poniard Pharmaceuticals) | Post-IPO Equity | 65M |
| 12/2004 | CymaBay Therapeutics | Series B | 44M |
| 3/2009 | Accriva Diagnostics | Venture Round | - |
| 8/2004 | Avera Pharmaceutical | Series C | 0 |
| 3/1999 | VNUS Medical Technologies | Venture Round | - |
| 8/2007 | Presidio Pharmaceuticals | Series B | 26M |
| 12/2002 | Bioren | Seed Round | - |
| 8/2000 | Epocrates | Series B | 35M |
| 8/2002 | Epocrates | Series C | - |
| 1/2002 | BioSeek | Venture Round | - |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 5/2007 | Vivaldi Biosciences | Series A | 2M |
| 10/2014 | SynGen | Venture Round | - |
| 4/2012 | SynGen | Series A | 5M |
| 1/2018 | Oculis | Series B | 20.5M |
| 5/2021 | Oculis | Series C | 0 |
| 11/2000 | Panomics | Seed Round | - |
| 2/2002 | Syntonix Pharmaceuticals | Series B | 35.8M |
| 1/2008 | Aragon Surgical | Series B | 25M |
| 9/2007 | Aciex Therapeutics | Series A | - |
| 3/2002 | Reliant Pharmaceuticals | Series C | 160M |
| 1/2010 | Merus | Series B | 0 |
| 11/2009 | CymaBay Therapeutics | Series E | 0 |
| 2/2011 | Conatus Pharmaceuticals | Series B | 0 |
| 1/1999 | Lexicon Pharmaceuticals | Post-IPO Equity | 0 |
| 5/2017 | Xeris Pharmaceuticals | Series C | 0 |
| 8/2003 | CymaBay Therapeutics | Series A | 27M |
| 9/2000 | Senomyx | Series B | 10M |
| 10/2016 | Bridge Medicines | Venture Round | - |
| 10/2013 | Galecto | Series B | 6.3M |
| 8/2000 | Intarcia Therapeutics | Venture Round | - |
| 1/2004 | PTC Therapeutics | Series E | 35M |
| 7/2016 | Vtesse | Series A | 17M |
| 6/2017 | Twist Bioscience | Venture Round | 27M |
| 10/2010 | IDEV Technologies | Series D | 46M |
| 6/2013 | Dermira | Series B | 35M |
| 9/2010 | EnteroMedics | Post-IPO Equity | 6.3M |
| 4/2009 | Sunesis Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2009 | Hyperion Therapeutics | Series C | 60M |
| 4/2014 | Madrigal Pharmaceuticals | Post-IPO Equity | - |
| 11/2000 | Helios Health | Venture Round | 0 |
| 7/2004 | EnteroMedics | Series A | - |
| 3/2007 | Phenomix | Series C | 55M |
| 3/2010 | Ion Torrent | Series C | 37.1M |
| 11/1997 | Maxia Pharmaceuticals | Venture Round | - |
| 1/1999 | LJL Biosystems | Post-IPO Equity | - |
| 11/2005 | PTC Therapeutics | Private Equity Round | 26.6M |
| 1/2014 | Fabric Genomics (formerly Omicia) | Series A | 6.8M |
| 1/2006 | MAP Pharmaceuticals | Series C | 25.2M |
| 9/2004 | MAP Pharmaceuticals | Series B | 30M |
| 10/2009 | Aviir | Venture Round | 1M |
| 6/2003 | Phenomix | Series A | 11.6M |
| 8/2005 | Protez Pharmaceuticals | Series B | 15M |
| 12/2008 | Aviir | Venture Round | 7.8M |
| 10/2005 | Radiant Medical | Venture Round | 36M |
| 6/2013 | Aviir | Series B | 10M |
| 1/2010 | Aviir | Venture Round | 4.2M |
| 1/1998 | Pharminex | Venture Round | - |
| 9/2006 | NuPathe | Series A | 15M |
| 9/2007 | Aviir | Series B | 11.3M |
| 10/2003 | Reliant Pharmaceuticals | Series D | 115M |
| 1/2016 | Imara | Seed Round | 800k |
| 11/2012 | Ascendancy | Venture Round | - |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 11/2009 | Calypso Medical | Series E | 50M |
| 7/2012 | GenturaDx | Series C | 21M |
| 12/2003 | Avera Pharmaceutical | Series B | 8M |
| 12/2006 | NBI Development | Seed Round | 5.5M |
| 3/2007 | MAP Pharmaceuticals | Series D | 50M |
| 12/2011 | Aviir | Venture Round | 10M |
| 3/2008 | Aviir | Venture Round | 1.5M |
| 10/2020 | Sembiosys Genetics | Venture Round | - |
| 9/2001 | PTC Therapeutics | Series D | 0 |
| 9/2013 | Civitas Therapeutics | Series B | 0 |
| 2/2012 | Altheos | Series A | 12.5M |
| 6/2004 | PTC Therapeutics | Series E | 0 |
| 4/2010 | Altheos | Series A | 20M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 1/2018 | KBP Biosciences | Series A | 0 |
| 7/2004 | Phenomix | Series A | 2M |
| 3/2013 | Nabsys | Series D | 35M |
| 3/2019 | Imara | Series B | 0 |
| 10/2011 | Dermira | Series A | 42M |
| 2/2007 | PTC Therapeutics | Series F | 10M |
| 4/2016 | Imara | Series A | 31M |
| 10/2002 | Oculex Pharmaceuticals | Series B | 50M |
| 12/2006 | Nevro | Seed Round | 5.5M |
| 10/2013 | Merus | Series B | 42.2M |
| 4/2015 | Merus | Series C | 79.1M |
| 7/2011 | Nevro | Series B | 58M |
| 7/2013 | TRIA Beauty | Private Equity Round | 0 |
| 1/2011 | NextWave Pharmaceuticals | Series C | 45M |
| 9/2008 | Nevro | Series A | 21.8M |
| 10/2009 | Epizyme | Series B | 32M |
| 10/2002 | Pharmion | Venture Round | 40M |
| 8/2014 | Dermira | Series C | 51M |
| 8/2014 | Civitas Therapeutics | Series C | 0 |
| 3/2002 | Phenomix | Series A | 12M |
| 1/2015 | Vtesse | Series A | 25M |
| 3/2013 | Nevro | Series C | 0 |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 3/2020 | Xilio Therapeutics | Series B | 100.5M |
| 5/2007 | Conatus Pharmaceuticals | Series A | 22M |
| 7/2017 | Kezar Life Sciences | Series B | 0 |
| 11/2020 | Bridge Medicines | Equity | 10M |
| 11/2018 | NextCure | Series B | 93M |
| 2/2013 | Aviir | Series B | 10M |
| 2/2008 | Cadence Pharmaceuticals | Post-IPO Equity | - |
| 8/2000 | Syrrx | Series A | 5.1M |
| 6/2002 | Itamar Medical | Venture Round | - |
| 4/2002 | Avera Pharmaceutical | Series A | 20M |
| 1/2009 | Vivaldi Biosciences | Series A | 23M |
| 7/2008 | NuPathe | Series B | 30M |
| 3/2008 | BrainCells | Series B | 30M |
| 10/2013 | PharmAkea | Series A | 10M |
| 4/2005 | Phenomix | Series B | 20M |
| 12/2014 | Interleukin Genetics | Post-IPO Equity | 5M |
| 6/2011 | Aviir | Venture Round | 3M |
| 4/2012 | Thermogenesis | Post-IPO Equity | - |
| 7/2018 | Gossamer Bio | Series B | 0 |
| 3/2009 | VIA Pharmaceuticals | Debt Financing | 10M |
| 10/2017 | Gritstone Bio | Venture Round | - |
| 10/2013 | Cydan | Venture Round | 10M |
| 5/2021 | Oculis | Series C | 0 |
| 11/2020 | Bridge Medicines | Venture Round | 0 |
| 10/2020 | Sembiosys Genetics | Venture Round | - |
| 3/2020 | Xilio Therapeutics | Series B | 0 |
| 3/2019 | Imara | Series B | 0 |
| 11/2018 | NextCure | Series B | 0 |
| 7/2018 | Gossamer Bio | Series B | 0 |
| 1/2018 | KBP Biosciences | Series A | 0 |
| 1/2018 | Oculis | Series B | 0 |
| 10/2017 | Gritstone Bio | Venture Round | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
